Jonathan Minden is listed as an executive officer, director, and promoter on 2 SEC Form D filings by 1 issuer between Feb 2020 and Aug 2024: Impact Proteomics, LLC (Pittsburgh, PA — biotechnology — 2020–2024; $200K reported sold to 2 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Amber Lucas (1 shared filing) and Jeffrey Whitmore (1 shared filing).
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Jonathan. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 2 public filings for Jonathan Minden and found 3 differences: Jonathan Minden's role changed at Impact Proteomics, LLC: director → executive officer, director, promoter; No amendment in the last 12 months on an offering that may still be open; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.